STAT3 signaling induces the differentiation of human ICOS(+) CD4 T cells helping B lymphocytes

PLoS One. 2013 Jul 26;8(7):e71029. doi: 10.1371/journal.pone.0071029. Print 2013.

Abstract

The generation of high-affinity antibodies and the development of B cell memory are dependent on the help provided by CD4 T cells. Mouse studies indicate that STAT3 signaling in CD4 T cells promotes the acquisition of the B cell help function. However, the role of STAT3 in humans has been controversial. In this study, we show that IL-6 and other STAT3 activating cytokines (IL-21 and IL-27) induce the differentiation of CD4 T cells promoting antibody production by B cells. The acquisition of B cell stimulating properties by naive cord blood CD4 T cells required the STAT3-dependent expression of ICOS and IL-21. Gene reporter and ChIP experiments unambiguously demonstrated that upon IL-6 stimulation, STAT3 induces the transcription of the ICOS gene through direct recruitment to the proximal promoter region indicating that STAT3 acts in part through the direct activation of the ICOS gene.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibody Formation
  • B-Lymphocytes / cytology
  • B-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / cytology
  • CD4-Positive T-Lymphocytes / immunology*
  • CD4-Positive T-Lymphocytes / metabolism
  • Cell Differentiation
  • Cells, Cultured
  • Humans
  • Inducible T-Cell Co-Stimulator Protein / genetics
  • Inducible T-Cell Co-Stimulator Protein / immunology*
  • Interleukin-12 / immunology
  • Interleukin-27 / immunology
  • Interleukin-6 / immunology*
  • Lymphocyte Activation
  • Mice
  • STAT3 Transcription Factor / immunology*
  • Signal Transduction
  • Transcriptional Activation

Substances

  • ICOS protein, human
  • Inducible T-Cell Co-Stimulator Protein
  • Interleukin-27
  • Interleukin-6
  • STAT3 Transcription Factor
  • Interleukin-12

Grants and funding

This study was supported by the Fonds National de la Recherche Scientifique (FRS-FNRS, Belgium), an Interuniversity Attraction Pole grant of the Belgian Federal Science Policy and by the European Regional Development Fund and the Walloon Region. The Institute for Medical Immunology is co-funded by the government of the Walloon Region and GlaxoSmithKline Biologicals. LY is supported by the Télévie, FRS-FNRS. SG is a research associate and AM is a senior research associate of the FRS-FNRS. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.